Hardware Podcasts

#403: Global Perspective on Medical Device Reimbursement

Global Medical Device Podcast · 24 Apr 2025 · 37m · Episode 403

What this episode covers

Etienne Nichols interviews Karandeep Singh Badwal, a regulatory and reimbursement expert, about integrating reimbursement strategy into medical device development across the US, EU, and Asian markets. They discuss specific systems like US Medicare and CPT codes, EU fragmentation with national programs like Germany's NUB, and Asian pricing models, emphasizing that reimbursement must be a core business strategy from day one. Badwal highlights the importance of hiring jurisdiction-specific experts, leveraging post-market surveillance for real-world evidence, and using management reviews to align quality and business goals. The conversation concludes with a comparison of US and EU reimbursement pros and cons, stressing the need for strategic flexibility in a changing political landscape.

Most relevant to

early-stage companies and companies scaling up

Topics

Mentioned

Companies
Greenlight Guru
Also
Medicare, CPT, HCPCS, EU MDR, FDA, NHS, DEGA, NUB

Related episodes from other shows

Other shows on the same ground, closest first.

  • Let's Combinate · 37m

    062 - Reimbursement in Europe, Access, Rebates, and Negotiation with Stefan Walzer

    Dr. Stefan Walzer, CEO of MArS Market Access & Pricing Strategy, explains the complexities of European reimbursement, focusing on Germany's AMNOG process, mandatory discounts, and the role of Quality Adjusted Life Years (QALYs) in pricing negotiations. He details how payers use evidence packages, health economic models, and reference pricing to determine reimbursement, noting that mandatory discounts often fail to save systems money long-term as companies adjust list prices. Walzer also discusses his Negotiation Lab, which uses virtual reality simulations to train stakeholders in high-stakes pricing negotiations, and emphasizes the importance of preparation and stress management in achieving favorable outcomes.

    Pricing, margins & unit economicsPolicy, trade & tariffs
    10 chapters

  • Let's Combinate · 44m

    058 - PMSR Globally, Different Clinical Roles and Risk Management with Khaudeja Bano

    Dr. Khaudeja Bano, Vice President of Combination Product Quality at Amgen, discusses the global regulatory landscape for post-market surveillance reporting (PMSR) and the distinct clinical roles within pharmaceutical and medical device companies. She explains how risk management must be integrated into a closed-loop lifecycle, contrasting the condensed timelines of device development with the extended phases of pharmaceutical trials. Bano details the organizational structures of medical affairs, pharmacovigilance, and clinical teams, highlighting the significant variability in global reporting requirements and the ongoing challenges in harmonization across different geographies.

    Quality & yieldCertification & compliance
    7 chapters

  • Let's Combinate · 1h 13m

    044 -“Market Access” with Kasem Akhras

    Dr. Kasem Akhras, Senior Director at Novartis and author of 'Frontiers in Market Access', explains the evolution of market access from the 1980s to the present, detailing how managed care organizations shifted power from physicians to payers. He defines 'translational access' as the integration of health economics and outcomes research (HEOR) into early clinical development to shape Target Product Profiles (TPP) and secure reimbursement. Akhras discusses value-based pricing models, including cost-per-quality-adjusted-life-year (QALY) metrics, and explains why US pharmaceutical prices are higher due to statutory discounts and a fragmented, for-profit system compared to international reference pricing.

    Pricing, margins & unit economicsValidation & product-market fit
    7 chapters

  • Let's Combinate · 21m

    216 - How UAE and Singapore Are Redefining Regulatory Innovation with Stephen O'Rourke

    Stephen O'Rourke, founder of the consultancy Clarifi, discusses regulatory strategy for MedTech, biotech, and novel food startups navigating EU and US pathways. He highlights the hidden costs of regulatory failure, emphasizing the need for early engagement with agencies and the importance of UDI compliance across all departments. O'Rourke also explores emerging regulatory models in the UAE and Singapore, explaining how regulatory sandboxes and national initiatives are accelerating innovation, and shares insights from his run for the European Parliament on how policy is made.

    Policy, trade & tariffsCertification & compliance
    7 chapters

  • Let's Combinate · 59m

    027 - "Become a Historian of the Problem" with Duane Mancini

    Duane Mancini, CEO and Managing Partner of Project Medtech, discusses his transition from medicinal chemistry to medical device regulatory strategy at NAMSA and LabCorp. He explains the critical importance of integrating reimbursement strategy early in the development of combination products to avoid commercialization failures, noting that regulatory choices like 510(k) can negatively impact reimbursement pathways. Mancini details how Project Medtech supports startups through its podcasts, Startup Symposiums, and consulting services, focusing on capital raising, milestone mapping, and navigating the complexities of drug-device combinations like insulin patches.

    Crowdfunding & preordersValidation & product-market fit
    8 chapters

The summary, chapters and topics are generated from the episode’s audio by this directory, not written by Global Medical Device Podcast. The episode itself belongs to its publisher.